Vurderingen af de behandlingsrelaterede bivirkninger bygger på poolede data fra CCR5- tropisme HIV- 1 inficerede patienter, der fik den anbefalede dosis i to fase 3- forsøg (MOTIVATE- 1 og MOTIVATE- 2).
Assessment of treatment related adverse reactions is based on pooled data at the recommended dose from two Phase 3 studies (MOTIVATE 1 and MOTIVATE 2) in CCR5-tropic HIV-1 infected patients.